These novel medications , Semaglutide , represent a groundbreaking advancement in treating metabolic dysfunction and potentially related ailments . They are categorized as GLP-1 pathway stimulators, indicating they function to emulate the body's GLP-1 substance , boosting insulin secretion and lo